{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:50:44Z","timestamp":1781632244522,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.lungcan.2008.06.017","type":"journal-article","created":{"date-parts":[[2008,8,10]],"date-time":"2008-08-10T04:13:36Z","timestamp":1218341616000},"page":"60-65","source":"Crossref","is-referenced-by-count":20,"title":["Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer"],"prefix":"10.1016","volume":"64","author":[{"given":"Tim","family":"Eisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Thatcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Leyvraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Wilson H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Couture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"L\u00fcthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Tanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2008.06.017_bib1","unstructured":"Page NC, Read WL, Tierney RM. The epidemiology of small cell lung carcinoma. Proc ASCO 2002:305a."},{"issue":"2","key":"10.1016\/j.lungcan.2008.06.017_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.critrevonc.2004.08.005","article-title":"Treatment of small cell lung cancer","volume":"52","author":"Kurup","year":"2004","journal-title":"Crit Rev Oncol Hematol"},{"issue":"15","key":"10.1016\/j.lungcan.2008.06.017_bib3","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1056\/NEJM198704093161504","article-title":"Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung","volume":"316","author":"Perry","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2008.06.017_bib4","doi-asserted-by":"crossref","first-page":"259S","DOI":"10.1378\/chest.123.1_suppl.259S","article-title":"Small cell lung cancer","volume":"123","author":"Simon","year":"2003","journal-title":"Chest"},{"issue":"Suppl 5","key":"10.1016\/j.lungcan.2008.06.017_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/annonc\/mdj961","article-title":"Chemotherapy advances in small cell lung cancer","volume":"17","author":"Rosti","year":"2006","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2008.06.017_bib6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/jjco\/27.3.166","article-title":"Second-line chemotherapy for relapsed small cell lung cancer","volume":"27","author":"Ebi","year":"1997","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2008.06.017_bib7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1378\/chest.110.1.165","article-title":"Retreatment of patients surviving cancer-free 2 or more years after initial treatment of small cell lung cancer","volume":"110","author":"Chute","year":"1996","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2008.06.017_bib8","doi-asserted-by":"crossref","first-page":"s85","DOI":"10.1016\/0169-5002(93)90008-L","article-title":"Treatment options for patients with relapsed small cell lung cancer","volume":"9","author":"Greco","year":"1993","journal-title":"Lung Cancer"},{"issue":"49","key":"10.1016\/j.lungcan.2008.06.017_bib9","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1038\/sj.onc.1205972","article-title":"Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta","volume":"21","author":"Garcia-Fernandez","year":"2002","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.lungcan.2008.06.017_bib10","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1124\/mol.106.025569","article-title":"Plitidepsin cellular binding and Rac1\/JNK pathway activation depend on membrane cholesterol content","volume":"70","author":"Suarez","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"27","key":"10.1016\/j.lungcan.2008.06.017_bib11","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/sj.onc.1207636","article-title":"JNK activation is critical for aplidin-induced apoptosis","volume":"23","author":"Cuadrado","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2008.06.017_bib12","series-title":"AACR Annual Meeting; 2007 April 14\u201318 (abstract number 5580)","article-title":"JNK activation as an in vivo marker of Aplidin\u00ae","author":"Mu\u00f1oz","year":"2007"},{"issue":"1","key":"10.1016\/j.lungcan.2008.06.017_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1074\/jbc.M201010200","article-title":"Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK","volume":"278","author":"Cuadrado","year":"2003","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.lungcan.2008.06.017_bib14","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/sj.cdd.4401898","article-title":"Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation","volume":"13","author":"Gonzalez-Santiago","year":"2006","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.lungcan.2008.06.017_bib15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.leu.2402788","article-title":"a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4","volume":"17","author":"Broggini","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.lungcan.2008.06.017_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00280-005-0014-7","article-title":"Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes","volume":"57","author":"Straight","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2008.06.017_bib17","unstructured":"Anthoney A, Paz-Ares L, Twelves C. Phase I and pharmacokinetic (PK) study of Aplidin (APL) using a 24 hour, weekly schedule. Proc Am Soc Clin Oncol 2000;Abstract 734."},{"key":"10.1016\/j.lungcan.2008.06.017_bib18","unstructured":"Bowman A, Izquierdo MA, Jodrell D, Martinez M, Cicchella B, Jimeno J. Phase I clinical and pharmacokinetic (PK) study of the marine compound aplidin (APL), administered as a 1 hour weekly infusion. Proc Am Soc Clin Oncol 2001;Abstract 476."},{"issue":"31","key":"10.1016\/j.lungcan.2008.06.017_bib19","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1200\/JCO.2005.09.357","article-title":"Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies","volume":"23","author":"Faivre","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lungcan.2008.06.017_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00001813-200404000-00003","article-title":"Progress in the clinical development of new marine-derived anticancer compounds","volume":"15","author":"Jimeno","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.lungcan.2008.06.017_bib21","unstructured":"Ciruelos EM, Twelves C, Dominguez MJ, Mckay H, Anthony A, Castellanos D. Phase I clinical and pharmacokinetic study of the marine compound aplidin (APL) administered as a 3 hour infusion every 2 weeks. Proc Am Soc Clin Oncol 2002;Abstract 422."},{"key":"10.1016\/j.lungcan.2008.06.017_bib22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/annonc\/mdl165","article-title":"I study of Aplidine in a daily \u00d75 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115","volume":"17","author":"Maroun","year":"2006","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.lungcan.2008.06.017_bib23","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"Somerfield MRftASoCOGFEP. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.06.017_bib24","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.1999.17.9.2971","article-title":"Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology","volume":"17","author":"Gralla","year":"1999","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2008.06.017_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2008.06.017_bib26","unstructured":"National Cancer Institute Common Toxicity Criteria. Version 2.0, June 1, 1999. Available at: http:\/\/ctep.info.nih.gov. Accessed January 20, 2005."},{"key":"10.1016\/j.lungcan.2008.06.017_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"8","key":"10.1016\/j.lungcan.2008.06.017_bib28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/JTO.0b013e3180986262","article-title":"Current status of second-line treatment and novel therapies for small cell lung cancer","volume":"2","author":"Tiseo","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2008.06.017_bib29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00280-005-0157-6","article-title":"Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial","volume":"58","author":"Dongiovanni","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.lungcan.2008.06.017_bib30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11912-006-0030-8","article-title":"Second-line treatment of small-cell lung cancer","volume":"8","author":"MacCallum","year":"2006","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"10.1016\/j.lungcan.2008.06.017_bib31","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1634\/theoncologist.12-10-1194","article-title":"Recent advances with topotecan in the treatment of lung cancer","volume":"12","author":"O\u2019Brien","year":"2007","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.lungcan.2008.06.017_bib32","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2008.06.017_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0169-5002(02)00072-7","article-title":"Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer\u2014what limits limited disease?","volume":"37","author":"Micke","year":"2002","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500208003644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500208003644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T02:16:28Z","timestamp":1557713788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500208003644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0169500208003644"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2008.06.017","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}